Chu 2006c.

Methods	4‐Week dietary stabilisation period 3‐Month before‐and‐after study
Participants	32 men and women with hypercholesterolaemia; TC > 200 mg/dL (5.17 mmol/L), LDL‐C > 130 mg/dL (3.36 mmol/L) Exclusion criteria: any acute illness, leukocytosis, thrombocytosis, chronic inflammatory disease, connective tissue disease, individuals with ACS within 6 months of enrolment Baseline TC: 6.60 mmol/L (255 mg/dL) Baseline LDL‐C: 4.61 mmol/L (178 mg/dL) Baseline HDL‐C: 1.09 mmol/L (42 mg/dL) Baseline TG: 1.76 mmol/L (156 mg/dL)
Interventions	Atorvastatin 10 mg/d
Outcomes	Per cent change from baseline at 3 months of serum TC, LDL‐C, HDL‐C and TG
Notes	SDs were imputed
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Atorvastatin 10 mg/d; intervention was analysed, and as no placebo group was included for comparison, assessment of random sequence generation is not applicable
Allocation concealment (selection bias)	Unclear risk	Atorvastatin 10 mg/d; intervention was analysed, and as no placebo group was included for comparison, assessment of allocation concealment is not applicable
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Atorvastatin 10 mg/d; intervention was analysed, and as no placebo group was included for comparison, blinding status is not applicable
Incomplete outcome data (attrition bias) All outcomes	Low risk	Data on all participants were reported
Selective reporting (reporting bias)	Low risk	All lipid parameters were measured
Other bias	Low risk	The study appears to be free of other sources of bias